FAT10 is a member of the ubiquitin-like modifier family of proteins and has been implicated to play important roles in antigen presentation, cytokine response, apoptosis and mitosis. We have recently demonstrated the upregulation of FAT10 gene expression in 90% of hepatocellular carcinoma patients. Here, we identified and characterized the promoter of the FAT10 gene to elucidate the mechanism of FAT10 gene expression. Notably, we found that the 5 0 untranslated region (5 0 UTR), from the transcription start site to 15 bases before the translational start site, displays significant promoter activity. Regions upstream of the 5 0 UTR (from þ 26 to À1997) do not confer any promoter activity. Curiously, FAT10 promoter activity and expression is significantly repressed in KB3-1 and HepG2 cells, which have wild-type p53, than in p53-negative Hep3B cells. The role of p53 in regulating FAT10 expression was evident by the significant downregulation (Po0.05) of FAT10 mRNA expression and promoter activity when wild-type p53 was transfected into p53-null Hep3B cells. Conversely, inhibiting p53 expression through siRNA against p53 significantly enhanced FAT10 expression and promoter activity. p53 was found to bind in vivo to the 5 0 half consensus sequence of p53-binding site located at the FAT10 promoter. Hence, we propose that FAT10 is a downstream target of p53 and dysregulation of FAT10 expression in p53-defective cells could contribute to carcinogenesis.
Introduction
Dysregulation of cell-cycle and/or apoptotic controls are hallmarks of the tumorigenesis process. p53, hailed as the 'guardian of the genome' (Lane, 1992) , plays important roles in the regulation of cell cycle, response to DNA damage and apoptosis (Levine, 1997; Haupt et al., 2002; Vousden and Lu, 2002) . p53 is a nuclear phosphoprotein that acts as a transcriptional regulator to modulate the expression of numerous downstream target genes both positively and negatively (el-Deiry, 1998; Ho and Benchimol, 2003) . It can trans-activate cell-cycle/apoptotic genes, like MDM2, p21
WAF1/CIP1 and BAX, through the binding of a consensus sequence, 5 0 -PuPuPuC(A/T)(A/T)GPyPyPy-3 0 (two copies separated by 0-13 bp), in the target gene (el-Deiry, 1998; Vogelstein et al., 2000) . p53 is also able to repress the transcription of various genes including genes that regulate apoptosis (e.g. survivin) (Hoffman et al., 2002) and the G2/M phase of cell cycle (e.g. cyclin B1, cdc2, cdc25c, Mad1) (Innocente et al., 1999; Zhao et al., 2000; Chun and Jin, 2003) . The mechanism of repression of genes by p53 is less clear. Transcriptional repression by p53 is thought to occur through a few different mechanisms (Ho and Benchimol, 2003) . p53 can directly bind to DNA via either the p53 consensus sequences or other novel sequences to repress promoter activity. The binding of p53 to the promoter (e.g. AFP promoter) competitively displaces the binding of another stronger transcriptional activator (e.g. HNF-3) to the same promoter resulting in repression of the gene . In the majority of promoters that are repressed by p53, no p53 consensus sequences can be identified. Transcriptional repression of these genes may occur either through physical interactions with transcriptional activators, for example HNF4a1, rendering them inactive (Maeda et al., 2002) , interfering with the basal transcriptional machinery, for example the TATA-binding protein (Farmer et al., 1996) , or through the recruitment of histone deacetylases (HDACs) and chromatin remodeling, for example MAD1 (Chun and Jin, 2003) .
Dysregulation of p53 is a common phenomenon in most human cancers. In some tumors, p53 is sequestered in the cytoplasm of the cell, rendering it unable to function as a transcription factor (Moll et al., 1992) . In others, p53 is inactivated by interaction with viral proteins or other cellular proteins (Vogelstein et al., 2000) . Deletion or mutation of p53 can be observed in approximately half of these tumors. Majority of the naturally occurring mutations in p53 are in the DNA-binding domain and these mutations were found to attenuate p53 ability to trans-activate genes (Vogelstein et al., 2000) .
Members of ubiquitin-related family have also been implicated to be involved in the regulation of cell cycle (Jentsch and Pyrowolakis, 2000) as well as apoptosis (Jesenberger and Jentsch, 2002) . One member of this family is FAT10, which is also known as diubiquitin. The 18 kDa FAT10 protein comprises 165-amino-acid residues and belongs to the ubiquitin-like modifier (UBL) family of proteins (Jentsch and Pyrowolakis, 2000) . It contains two ubiquitin-like domains joined by a short linker and is 29% identical to ubiquitin at its N-terminus and 36% identical at the C-terminus. Role of FAT10 in cell-cycle regulation has been suggested by its ability to bind to MAD2, a spindle checkpoint protein (Liu et al., 1999) . We recently reported that the FAT10 gene is upregulated in various cancers (Lee et al., 2003) , implicating its role in tumorigenesis.
To elucidate the mechanism of FAT10 gene regulation, we isolated and characterized the promoter of FAT10. Interestingly, we found significant promoter activity in the 5 0 untranslated region (UTR) ( þ 1 to þ 209 bp) of the FAT10 gene but no promoter activity in regions upstream of the 5 0 UTR alone (from þ 26 to À1997 bp). Region À975 to þ 209 conferred maximum promoter activity. Significantly, we found that the FAT10 promoter is negatively regulated by p53. Hence, FAT10 may be a downstream target of p53 contributing to the tumorigenesis process.
Results
FAT10 promoter resides at the 5 0 UTR To better understand the regulation of FAT10 gene expression, we proceeded to identify the promoter of FAT10. We were unable to identify the putative promoter region using in silico strategies. We thus introduced various regions upstream of the transcription start site (TSS) and translation start site (TLSS) of the FAT10 gene into a reporter construct (Figure 1a , left panel) and quantitated its promoter activity. As shown in Figure 1a (right panel), regions from around the TSS ( þ 26 bp) to À1997 bp upstream of the TSS (constructs FAT(À975/ þ 26), FAT(À1716/ þ 26) and FAT(À1997/ þ 26)) did not display significant promoter activity. Promoter activity was evident only when more of the 5 0 UTR region (from þ 116) of FAT10 was included (constructs FAT(À366/ þ 116), FAT(À975/ þ 116), FAT(À1716/ þ 116) and FAT(À1997/ þ 116)). More than twofold enhancement of promoter activity was observed when nearly the entire 5 0 UTR (till 15 bp before the TLSS) was included (constructs FAT(À366/ þ 209), FATprom, FAT(À1716/ þ 209) and FAT(À1997/ þ 209)) compared to when only partial 5 0 UTR was included (constructs FAT(À366/ þ 116), FAT(À975/ þ 116), FAT(À1716/ þ 116) and FAT(À1997/ þ 116), respectively). Significantly, the entire 5 0 UTR alone was able to confer significant promoter activity (construct
0 UTR is capable of mediating significant promoter activity, with region þ 116 to þ 209 (construct FAT( þ 116/ þ 209)) conferring higher FAT10 promoter activity compared to region þ 1 to þ 116 (construct FAT( þ 1/ þ 116)). Maximum promoter activity was observed in a 1.18 kb fragment upstream of the TLSS (from þ 209 to À975 bp) (construct FATprom). Curiously, construct FAT(À1235/ þ 209) resulted in a significantly reduced promoter activity compared to construct FAT(À975/ þ 209) or FAT(À1716/ þ 209), suggesting that regions between À1235 and À975 may contain a silencer element.
Putative transcription binding sites were identified using the MatInspector program in the 1.18 kb region of FAT10 gene (Figure 1a , right panel, construct FATprom) that conferred the highest promoter activity (Figure 1b) . A TATA box residing between þ 163 and þ 177 bp was identified in this fragment. However, this TATA box is not essential since significant promoter activity was observed when this region was mutated ( Figure Other potentially interesting binding sites include those that play a role in interferon (IFN; e.g. IRF-1, IRF-2 and STAT-1), tumor necrosis factor (TNF; e.g. NF-kB) (Boehm et al., 1997) and retinoid (e.g. MZF-1) responsiveness. The existence of these responsive sites is consistent with the observations that the expression of FAT10 can be induced by IFN-g, TNF-a and/or retinoids (Raasi et al., 1999; Dokmanovic et al., 2002) .
FAT10 promoter activity and expression is low in p53-positive cell lines (KB3-1 and HepG2) but high in p53-negative Hep3B cell line We proceeded to examine the promoter function of FAT10 in different cell lines including KB3-1, HepG2 and Hep3B using the constructs FAT(À1716/ þ 116), FATprom and FAT(À1997/ þ 209). As evident in Figure 2a , the FAT10 promoter activity using all three constructs was significantly lower in KB3-1 and HepG2 cells compared with Hep3B cells. Similarly, FAT10 expression, as determined by reverse transcriptionpolymerase chain reaction (RT-PCR) and Western blot, was lower in KB3-1 and HepG2 compared to Hep3B cells (Figure 2b) . A feature that distinguishes KB3-1 and HepG2 cells from Hep3B cells is the p53 status.
The former two cell lines have normal functioning p53, whereas p53 in Hep3B cells is deleted ( Figure 2b ) (Bressac et al., 1990; Stahler and Roemer, 1998) . These results suggest that p53 may play a role in regulating FAT10 gene expression by repressing FAT10 promoter activity.
p53 negatively regulates FAT10 promoter activity To test the hypothesis that p53 represses FAT10 promoter activity, we introduced wild-type (wt) p53 into p53
À/À Hep3B cells. As shown in Figure 3a , FAT10
promoter activity is significantly inhibited in cells transfected with FATprom, FAT(À1176/ þ 209) or FAT(À1997/ þ 209) and wt p53 compared to cells transfected with similar FAT10 promoter constructs and vector control. Similarly, endogenous FAT10 transcript expression was also found to be significantly repressed when wt p53 rather than vector control was introduced into these Hep3B cells ( Figure 3b ). We also demonstrate that this repression can be reversed by the addition of siRNA against p53. Constructs pH1-sip53, whereby the siRNA against p53 is driven by the H1 polymerase III promoter ( Figure 4a , (Table 1) and FATmutTATA-R were utilized to generate the FATprom TATA-Mut construct, whereas primers FAT( þ 1)-F (Table 1) Notably, when endogenous p53 expression in KB3-1 and 293 cells was inhibited using siRNA against p53, significantly enhanced FAT10 promoter activity (Po0.01) was observed (Figure 4b ). Likewise, when siRNA against p53 was transfected into 293 cells, p53 expression was significantly inhibited (Figure 4c , top right panel), resulting in the inhibition of expression of known p53-regulated target genes including p21 and MDM2 (Vousden and Lu, 2002) (Figure 4c , bottom two panels) but not genes that are not regulated by p53, for example b-actin. Importantly, when endogenous p53 expression in 293 cells was inhibited by siRNA against p53, endogenous FAT10 expression was increased significantly (Figure 4c , top left panel).
These series of experiments unequivocally demonstrate the role of p53 in negatively regulating the promoter of FAT10. p53 binds to the 5 0 half consensus sequence of p53-binding site of the FAT10 promoter and plays a role in the responsiveness of FAT10 promoter to p53 In silico analyses of the region of the FAT10 promoter that conferred highest activity revealed a putative 5 0 half consensus sequence of p53-binding site residing between À240 and À220 bp upstream of the TSS (Figure 1b) . To determine if this region confers responsiveness of the promoter to p53, we mutated this putative p53-binding half-site (Figure 5a ) and compared their activity in the presence or absence of p53. As shown in Figure 5b , its responsiveness to p53 was abrogated by this mutation, as evident by the similar promoter activity in the presence or absence of p53 in cells transfected with pFATpromp53mut, suggesting that the p53-binding half-site plays an important role in determining the responsiveness of the FAT10 promoter to p53. Curiously, this mutation resulted in a significant attenuation of FAT10 promoter activity as evident by the significantly lower reporter activity when pFATpromp53mut containing the pFATpromp53mut compared to those containing the pFATprom construct (data not shown), revealing that this inhibition of promoter activity is independent of the p53 status. This is probably due to creation of an additional transcriptional repressorbinding site or the abolishment of a transcription activator-binding site when that site was mutated. In silico examination using the MatInspector program (http://www.genomatix.de/) did not reveal the abolishment or creation of known transcription activator/ repressor sites. Nonetheless, it does not rule out that novel transcription factor-binding sites may be created or abolished or that there are other yet unknown mechanisms for its repression.
To determine if p53 binds to this consensus site to repress FAT10 expression in cells, in vivo DNA immunoprecipitation assay was performed. As shown in Figure 5c , when FATprom or vector control constructs were transfected into Hep3B cells and the cells were immunoprecipitated with anti-b-actin or antip53 antibodies, respectively, only basal amplification of the FAT10 promoter region encompassing the putative p53-binding half-site was observed. However, significant enrichment (Po0.01) of this region was observed via real-time PCR when FATprom-transfected cells were immunoprecipitated with anti-p53 antibodies. Notably, when the p53-binding half-site was mutated, the affinity of binding of p53 to that site decreased significantly compared to the wt promoter (Po0.01) (Figure 5c ). To evaluate if p53 binds the chromatin region around the p53 consensus half-site of the endogenous FAT10 promoter in vivo, pCMV-p53 or vector control was transfected into Hep3B cells and chromatin immunoprecipitation (ChIP) assays were performed with antip53 or anti-b-actin antibodies. As evident in Figure 5d , amplification of the chromatin region encompassing the p53 consensus half-site was evident only in cells transfected with pCMV-p53 and immunoprecipitated with anti-p53 antibodies. No amplification was observed in the control lanes.
These results suggest that p53 directly binds to the FAT10 promoter, primarily at the p53-binding half-site region located between À240 and À220 bp upstream of the TSS and negatively modulates FAT10 promoter activity.
Discussion
FAT10 is an interesting molecule from at least two perspectives. It is of interest to immunologists as it may potentially play a role in immune regulation. FAT10 gene is localized to the telomeric end of the cluster of human major histocompatibility complex (MHC) class I (Fan et al., 1996) genes. In addition, it is expressed in dendritic cells and mature B cells (Bates et al., 1997) and can be synergistically induced by the IFNg and TNF-a cytokines (Raasi et al., 1999) . Although the FAT10 gene resides at the telomeric end of the MHC class I genes, it was reported not to be a member of this class of genes 
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DW Zhang et al (Kumanovics et al., 2003) . In this study, we show that the promoter architecture of the FAT10 gene (Figure 1b) is quite unlike the promoters of MHC class I genes. It contains a single rather than two NF-kB sites upstream of the IFN-stimulated response elements like the IRF-1 and IRF-2. Furthermore, it does not contain the site-a or enhancer B element (inverted CCAAT box) commonly seen in MHC I genes (van den Elsen et al., 1998).
FAT10 is also interesting to cancer biologists because of its potential role in cell-cycle/apoptosis regulation and tumorigenesis. FAT10 belongs to the UBL family whose members have been implicated to play important roles in cell-cycle regulation/apoptosis (Jentsch and Pyrowolakis, 2000; Jesenberger and Jentsch, 2002) . Furthermore, it comprises two ubiquitin-like domains fused in tandem. The ubiquitin pathway is an important þ / þ KB3-1 and 293 cells. KB3-1 cells were initially either untransfected or transfected with pH1-Sip53 or pH1-control (control). After 24 h, these cells were transfected with FATprom (see Figure 1 ) and FAT10 promoter activity was assayed 48 h later. The top panel shows normalized FAT10 promoter activity from 11 (KB3-1) or 8 (293) separate experiments (mean7s.e.). ** denotes significant difference at Po0.01 between cells transfected with pH1-Sip53 þ FATprom and pH1-control þ FATprom or FATprom alone. The lower panels show Western blot of these two types of cells hybridized with either anti-p53 or anti-b-actin antibodies. (c) FAT10 expression is enhanced by the addition of siRNA against p53 in p53 þ / þ 293 cells. 293 cells are transfected with either pH1-control or pH1-Sip53, and FAT10, p53, p21 and MDM2 expression was quantitated using either real-time RT-PCR or densitometry. The figure shows relative FAT10 transcript levels (normalized against b-actin) from three different experiments (mean7s.e.). ** denotes significant difference at Po0.01 between cells transfected with control siRNA and siRNA against p53.
FAT10 is negatively regulated by p53 DW Zhang et al Figure 5 The 5 0 half consensus sequence of p53-binding site at the FAT10 promoter binds to p53 and is responsible for the responsiveness of the promoter to p53. (a) Primers and strategy for generating the p53-binding half-site mutant. The p53-binding halfsite mutant was generated via a two-step PCR. In the first step, two separate PCR products were generated using the following pairs of primers: (1) FAT(À975)-F and Muta-p53-R and (2) Muta-p53-F and FAT( þ 209)-R. The purified and amplified PCR products were then combined and amplified using primers FAT(À975)-F and FAT( þ 209)-R. (b) The putative p53-binding half-site of the FAT10 promoter regulates the promoter's responsiveness to p53. Normalized promoter activity in Hep3B cells from four separate experiments (mean7s.e.) is presented in the top panel. ** denotes significant difference (Po0.01) between the various FAT promoter constructs þ control and the various FAT10 promoter constructs þ pCMV-p53. Western blot analyses of these cells using anti-p53 and anti-b-actin (Actin) antibodies are presented in the middle two panels. Pictorial representation of the different FAT10 promoter constructs is given in the lowest panel. (c) FAT10 promoter region encompassing the p53-binding half-site binds p53 in vivo. FATprom or FATpromp53mut construct was co-transfected with either pCMV-p53 or vector control into Hep3B cells. DNA immunoprecipitation assay was performed with anti-p53 or control b-actin antibodies. (a) Agarose gel representation of the PCR product after 25 cycles using primers 100 bp upstream and downstream of the p53-binding half-site of the FAT10 promoter. (b) Realtime PCR quantitation of the PCR product, which was normalized against input chromatin to correct for differences in the amount of DNA present in the different samples. 'Precipitated' denotes chromatin that has been crosslinked, immunoprecipitated with either antip53 or anti-actin antibodies, reverse crosslinked and DNA extracted; 'Input' denotes total chromatin that has been crosslinked (but not immunoprecipitated), reverse crosslinked and DNA extracted. ** denotes significant difference (Po0.01) between the amount of FATprom immunoprecipitated by p53 antibody and FATprom immunoprecipitated by b-actin antibody or FAT-p53mut or vector control immunoprecipitated by p53 antibody. (d) Endogenous FAT10 promoter region encompassing the p53-binding half-site binds p53 in vivo. pCMV-p53 or vector control construct was transfected into Hep3B cells. ChIP assay was performed with anti-p53 or control b-actin antibodies. The figure shows agarose gel representation of the PCR product after 33 cycles using primers 100 bp upstream and downstream of the p53-binding half-site of the FAT10 promoter or primers within exon 2 of the FAT10 gene.
DW Zhang et al player in cell-cycle regulation (Pines, 1994; Pagano, 1997) . Additionally, FAT10 was found to interact with MAD2, a mitotic spindle checkpoint protein (Liu et al., 1999) that has been shown to be important for maintaining genome stability (Michel et al., 2001) . Dysregulation of MAD2 has also been implicated in tumorigenesis (Michel et al., 2001; Wang et al., 2002; Li et al., 2003) . Notably, FAT10 expression was found to be upregulated in hepatocellular carcinoma (HCC) and other gastrointestinal and gynecological cancers (Lee et al., 2003) . For a better appreciation of the role of FAT10 in tumorigenesis, we identified and characterized its promoter to understand how the FAT10 gene is regulated or dysregulated. We found that the core promoter region of the FAT10 gene resides entirely within the 5 0 UTR. Regions upstream of the 5 0 UTR (exon 1) do not confer any promoter activity (Figure 1a , right panel). Basal promoter activity residing entirely in exon 1 was also reported in a few other genes including the SCA2 (Aguiar et al., 1999) and TIMP-1 (Clark et al., 1997) genes. Although the consensus sequence for a TATA box was identified in the promoter of FAT10 (Figure 1b) , this box was found not to be essential for promoter activity but to play a role in enhancing its activity. Maximal FAT10 promoter activity was found to be localized to the region between À975 and þ 209 of the gene (Figure 1a, right panel) .
Notably, we demonstrate through a series of experiments that FAT10 gene expression and promoter activity is negatively regulated by p53 (Figures 2-4) , implicating FAT10 in the pathway of p53 as a downstream gene. Hep3B cell line whose p53 is deleted showed higher FAT10 transcript expression and promoter activity compared to HepG2 and KB3-1 cell lines with wt p53 (Figure 2 ). In addition, the introduction of wt p53 into p53 À/À Hep3B cell line inhibited FAT10 transcript expression and promoter activity (Figure 3b and a), which can be alleviated by the addition of siRNA against p53 (Figure 4a) . Furthermore, siRNA against p53 enhanced FAT10 promoter activity in the p53 þ / þ KB3-1 and 293 cell lines (Figure 4b ) as well as FAT10 transcript expression in 293 cell line (Figure 4c) . Downstream target genes that are negatively regulated by p53 include genes regulating apoptosis (Hoffman et al., 2002) and the G2/M of the cell cycle (Innocente et al., 1999; Zhao et al., 2000; Chun and Jin, 2003) . One of the G2/M genes that are downregulated by p53 is MAD1 (Chun and Jin, 2003) . Both MAD1 (Luo et al., 2002) and FAT10 (Liu et al., 1999) are capable of interacting with MAD2, the spindle checkpoint protein whose dysregulation can lead to genomic instability and tumorigenesis (Michel et al., 2001; Hernando et al., 2004) .
Transcription repression of downstream target genes by p53 is thought to occur via one of a few mechanisms (Ho and Benchimol, 2003) . p53 may directly bind to p53 consensus to repress promoter activity or it may act through interference of the basal transcriptional machinery via the binding of p53 to the TATA-binding protein (Farmer et al., 1996) or the binding of other transcriptional factors. Other mechanisms of repression of the FAT10 promoter activity by p53 include the recruitment of HDAC1-mSin3a repression complex to the promoter, which was observed in the negative regulation of MAD1 by p53 (Chun and Jin, 2003) . Using in silico strategies, we identified a putative 5 0 half consensus sequence of p53-binding site (p53-binding half-site) residing between À240 and À220 bp of the FAT10 promoter (Figure 1b) . We demonstrated that when this site was mutated, the FAT10 promoter responsiveness to p53 was abrogated (Figure 5a) . Importantly, we demonstrate through DNA immunoprecipitation analyses that p53 binds to the FAT10 promoter in vivo via this consensus site, as the binding was significantly reduced (Po0.01) when this consensus site was mutated (Figure 5c ). Through ChIP analyses, we further demonstrate that p53 binds to this region of the endogenous FAT10 promoter (Figure 5d ).
In summary, p53 is likely an upstream regulator of FAT10 and may link FAT10 in the tumorigenesis process. The biological significance of p53-mediated repression of FAT10 gene in tumorigenesis warrants further investigation. As FAT10 was found to interact with MAD2, a mitotic checkpoint protein (Liu et al., 1999) , an attractive hypothesis would be that the repression of FAT10 expression by p53 may facilitate the interaction of MAD2 with cdc20 to induce mitotic arrest. During tumorigenesis, p53 may not function appropriately, leading to enhancement of FAT10 gene expression, observed in several different cancers (Lee et al., 2003) . More FAT10 interact with MAD2 resulting in the deregulation of mitosis, leading to genome instability and tumorigenesis.
Materials and methods
Identification of promoter region in the FAT10 gene As no putative promoter region in the FAT10 gene can be predicted using in silico strategies with programs from websites http://bimars.dcrt.nih.gov/molbio/proscan/ and http:// www.cbs.dtu.dk/services/Promoter/, various regions upstream of the TLSS or the reported TSS (Liu et al., 1999) were cloned to test for promoter activity. PCR was performed using human genomic DNA and primers (Table 1) designed according (Figure 5a ). All constructs were sequence verified to exclude PCR-induced nucleotide misincorporations before use. The MatInspector program (http://www.genomatix.de/) was utilized to predict putative transcription factor-binding sites.
The following cell lines were used in this study: KB3-1, a subclone of a HeLa cell line; 293, a human kidney cell line; HepG2, an HCC cell line with normal p53; and Hep3B, another HCC cell line but with its p53 deleted. The various FAT10 promoter-reporter constructs and/or p53 constructs were transfected into the different cell lines using either calcium phosphate co-precipitation as described previously (Lee et al., 2000) or SuperFectt Transfection Reagent (Qiagen).
b-Galactosidase activity was assayed using chlorophenol red-b-D-galactopyranoside as substrate in a kinetic assay at 570 nm with a SpectraMAX PLUS microplate reader (Molecular Devices), whereas EGFP fluorescence was quantitated at 509 nm using a SpectraMAX Gemini microplate reader (Molecular Devices) after excitation at 488 nm. The b-galactosidase activity was normalized against the EGFP activity to correct for differences in transfection efficiencies.
Quantitation of FAT10, p53, p21 and MDM2 and b-actin transcript RNA was isolated as described previously (Lee et al., 2003) . cDNA was synthesized from total RNA using Superscript II reverse transcriptase (Invitrogen) as per the manufacturer's instructions. Real-time PCR was performed in a Rotor-Gene 2000 Real-Time Thermal Cycler (Corbett Research) using the QuantiTectt SYBR s Green PCR Kit (Qiagen). Amplification reactions comprise 25 ng of cDNA template, 0.25 pmol/ml each of the forward and reverse primers for the various genes and 5 ml of 2 Â PCR Master Mix (Qiagen) in a total volume of 10 ml. The primers for the various genes are as follows:
0 -ATGTTTGAGACCTTCACACC, R: 5 0 -AGG TAGTCAGTCAGGTCCCGGCC). For amplification of the FAT10 transcript, its cDNA was denatured at 951C for 15 min followed by 45 cycles of amplification at 951C for 30 s, 641C for 30 s and 721C for 30 s, whereas p53, p21, MDM2 and b-actin amplification involved an initial denaturation at 951C for 15 min followed by 40 cycles at 951C for 30 s, 551C for 30 s and 721C for 30 s. SYBR s Green fluorescence was measured after each extension step. Standard curves for FAT10, p53, p21, MDM2 and b-actin were generated using serial dilution of plasmids containing the respective cDNAs. The linear range for all the respective gene expression was determined to be between 10 3 and 10 8 copies (r 2 for FAT10 is 0.9993, p53 is 0.9992, p21 is 0.9997, MDM2 is 0.9994 and b-actin is 0.992). FAT10, p53, p21 and MDM2 expression was normalized against the housekeeping b-actin gene expression. All RT-PCR reactions were performed in triplicate.
Generation of siRNA constructs against p53
The sense (5 0 -GATCCCGACTCCAGTGGTAATCTACTT CAAGAGAGTAGATTACCACTGGAGTCTTTTTTGGAA A-3 0 ) and antisense (5 0 -AGCTTTTCCAAAAAAGACTC CAGTGGTAATCTACTCTCTTGAAGTAGATTACCACT GGAGTCGG-3 0 ) (underlined nucleotides denote p53 sequences) (Brummelkamp et al., 2002) oligonucleotides of siRNA against p53 were annealed by heating the mixed oligonucleotides to 901C for 3 min, then cooled to 371C and incubated for 1 h. The annealed oligonucleotides were then cloned into the linearized vector, pSilencer 3.0-H1 (Ambion).
Determination of FAT10, p53 and b-actin protein levels Whole-cell lysates were electrophoresed on a 10% SDSpolyacrylamide gel and transferred onto a PVDF membrane (Bio-Rad). Proteins on the membrane were then probed with either anti-p53 antibody (1:5000) (mouse monoclonal IgG 2a ) (Santa Cruz Biotechnology), anti-FAT10 antibody (1:4000) (rabbit polyclonal) (Lee et al., 2003) or anti-b-actin antibody (1:4000) (goat polyclonal) (Santa Cruz Biotechnology) and either horseradish peroxidase-conjugated goat anti-mouse, goat anti-rabbit or rabbit anti-goat secondary antibodies (1:5000) (Pierce Biotechnology). Blots were then visualized using SuperSignalt Duro Reagent (Pierce Biotechnology).
Determination of the binding of p53 to FAT10 promoter region using DNA and chromatin immunoprecipitation To delineate the region of the FAT10 promoter that p53 binds to, FATprom or FATpromp53mut construct was co-transfected with either pCMV-p53 or vector control into Hep3B cells using calcium phosphate co-precipitation. Cells containing the various constructs were harvested 48 h after transfection and DNA immunoprecipitation was performed using the ChIP assay kit (Upstate Cell Signaling Solutions). Proteins and DNA in the transfected cells were crosslinked with 1% formaldehyde and then the DNA-protein complex was sheared through sonication and immunoprecipitated with either 1 mg of anti-p53 (Santa Cruz Biotechnology) or control anti-b-actin antibody. After reversing the crosslinked DNAprotein complex, DNA was recovered from the immunoprecipitate through phenol-chloroform extraction and ethanol precipitation. Real-time PCR was performed to quantitate the amount of specific FAT10 promoter region that binds p53. The input total lysate that has been crosslinked (but not immunoprecipitated), reverse crosslinked and DNA extracted was utilized to normalize for differences in the amount of DNA present in the different samples. Real-time PCR was performed in a Rotor-Gene 2000 Real-Time Thermal Cycler (Corbett Research) using the QuantiTectt SYBR s Green PCR Kit (Qiagen). Amplification reaction comprises 1 ml template and 0.25 pmol/ml of each of the primers (forward 5 0 -ATGGACACATAACCCAGGATG and reverse 5 0 -TTCTCGTTCCTTGAATTCCC). Primers for this realtime PCR assay were designed approximately 100 bp upstream and downstream of the 5 0 half consensus sequence of p53-binding site. Conditions for the amplification are denaturation at 951C for 15 min followed by 25 cycles at 951C for 30 s, 551C for 30 s and 721C for 30 s. Standard curve was generated using plasmids containing the fragment of DNA. The linear range for this amplification was determined to be between 10 2 and 10 8 copies (r 2 ¼ 0.998).
To demonstrate that the p53 binds to endogenous FAT10 promoter in vivo, Hep3B cells were transfected with either the pCMV-p53 construct or the vector construct and ChIP assay was performed using the ChIP assay kit (Upstate Cell Signaling Solutions) as described above except that 33 cycles instead of 25 cycles of amplification were performed. To show that the promoter region but not other regions of FAT10 is specifically amplified, PCR was also performed on the input lysate of immunoprecipitated chromatin using primers (forward 5 0 -CTGTCTTGTGGCTTTCACTTC and reverse 5 0 -TGCCTCTTTGCCTCATCACC) to amplify part of the exon 2 region of the FAT10 gene.
